BeiGene (NASDAQ:BGNE) Shares Gap Up to $231.32
BeiGene (NASDAQ:BGNE) Shares Gap Up to $231.32
BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) gapped up prior to trading on Wednesday . The stock had previously closed at $231.32, but opened at $240.23. BeiGene shares last traded at $237.49, with a volume of 80,293 shares trading hands.
百濟神州有限公司（NASDAQ：BGNE — 獲得評級）在周三交易之前就閃爍了。該股票之前已收盤 231.32 美元，但收盤價為 240.23 美元。百濟神州的股票最後交易價為 237.49 美元，交易量為 80,293 股。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
A number of research analysts have recently commented on the stock. Guggenheim restated a "buy" rating and set a $350.00 price target on shares of BeiGene in a research report on Tuesday, February 28th. Cowen increased their price objective on shares of BeiGene from $213.00 to $262.00 and gave the company an "outperform" rating in a research report on Tuesday, February 28th. StockNews.com raised shares of BeiGene from a "sell" rating to a "hold" rating in a research report on Saturday, November 19th. Daiwa Capital Markets started coverage on shares of BeiGene in a research note on Wednesday, January 11th. They issued a "buy" rating and a $308.00 target price for the company. Finally, Morgan Stanley decreased their target price on shares of BeiGene from $325.00 to $321.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 28th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $292.86.
一些研究分析師最近對該股發表了評論。2 月 28 日（星期二）的一份研究報告中，古根海姆重申了「買入」評級，並設定了百濟神州股票的價格目標為 350.00 美元。Cowen 將百濟神州股票的價格目標從 213.00 美元提高到 262.00 美元，並在 2 月 28 日（星期二）的一份研究報告中給予該公司「表現超越」評級。在 11 月 19 日（星期六）的一份研究報告中，Stocknews.com 將百濟神州的股票從「賣出」評級提高到「持有」評級。大和資本市場於 1 月 11 日（星期三）在研究報告中開始對百濟神州的股票進行報導。他們為該公司發布了「買入」評級和 308.00 美元的目標價格。最後，摩根士丹利將百濟神州股票的目標價格從 325.00 美元降至 321.00 美元，並在 2 月 28 日（星期二）的一份研究報告中設定了該股票的「超重」評級。一位研究分析師對該股票進行了保持評級，六名則為該公司的股票分配了買入評級。根據 MarketBeat 的數據，該公司目前的共識評級為「中等買入」，平均價格目標為 292.86 美元。
BeiGene Stock Up 1.7 %
百濟神州股票上漲 1.7%
The stock has a market capitalization of $24.53 billion, a P/E ratio of -12.33 and a beta of 0.77. The firm has a 50 day simple moving average of $245.20 and a two-hundred day simple moving average of $201.24. The company has a quick ratio of 3.35, a current ratio of 3.55 and a debt-to-equity ratio of 0.05.
該股的市值為 2453 億美元，市盈率為 -12.33，貝塔值為 0.77。該公司有一個 50 天的簡單移動平均線為 245.20 美元，以及 200 天的簡單移動平均線為 201.24 美元。該公司的快速比率為 3.35，流動比率為 3.55，債務與權益比率為 0.05。
BeiGene (NASDAQ:BGNE – Get Rating) last released its quarterly earnings data on Monday, February 27th. The company reported ($4.29) earnings per share for the quarter, missing analysts' consensus estimates of ($4.18) by ($0.11). The business had revenue of $380.10 million during the quarter, compared to analysts' expectations of $388.17 million. BeiGene had a negative net margin of 141.86% and a negative return on equity of 39.72%. The firm's quarterly revenue was up 77.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($6.22) earnings per share. On average, equities research analysts expect that BeiGene, Ltd. will post -12.44 earnings per share for the current year.
百濟神州（NASDAQ: BGNE — 獲取評級）最近一次發布了其季度收益數據，週一，2 月 27 日。該公司報告了本季度每股盈利（4.29 美元），缺失分析師的共識估計為（4.18 美元）（0.11 美元）。該業務在本季度的收入為 38,010 億美元，而分析師的預期為 38817 萬美元。百濟神州的負淨利潤率為 141.86%，負資產回報率為 39.72％。公司的季度收入較去年同期上升 77.6%。在上一年同一季度，該公司公佈了每股盈利（6.22 美元）。平均而言，股票研究分析師預計，百濟神州有限公司將在本年度公佈 -12.44 每股盈利。
Insiders Place Their Bets
內部人士下注
In other BeiGene news, insider Xiaodong Wang sold 67,635 shares of BeiGene stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $226.03, for a total value of $15,287,539.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other BeiGene news, CEO John Oyler sold 1,716 shares of BeiGene stock in a transaction dated Thursday, December 29th. The shares were sold at an average price of $224.46, for a total transaction of $385,173.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Xiaodong Wang sold 67,635 shares of the firm's stock in a transaction that occurred on Wednesday, March 8th. The stock was sold at an average price of $226.03, for a total transaction of $15,287,539.05. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 80,668 shares of company stock worth $18,469,758. Company insiders own 7.50% of the company's stock.
在其他百濟神州的消息中，內幕小東王於 3 月 8 日（星期三）在一次交易中出售了 67,635 股百濟神州股票。這些股票以平均價格 226.03 美元出售，總價值為 15,287,539.05 美元。出售是在與證券交易委員會的法律檔案中披露的，該交易可通過以下方式獲得 此超連結。在其他百濟神州的消息中，首席執行官約翰·奧勒（John Oyler）在 12 月 29 日（星期四）的一項交易中出售了 1716 股百濟神州股票。這些股份以 224.46 美元的平均價格出售，交易總額為 385,173.36 美元。出售是在與證券交易委員會的法律檔案中披露的，該交易可通過以下方式獲得 這個鏈接。此外，內幕小東王小東在 3 月 8 日（星期三）發生的一項交易中出售了該公司股票的 67,635 股。該股票以 226.03 美元的平均價格出售，總交易額為 15,287,539.05 美元。可以找到此次銷售的披露 這裡。在過去的九十天裡，內部人士已經賣出了 80,668 股價值 18,469,758 美元的公司股票。公司內部人士擁有公司股票的 7.50％。
Institutional Inflows and Outflows
機構流入和流出
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its stake in shares of BeiGene by 26.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 244 shares of the company's stock valued at $54,000 after buying an additional 51 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of BeiGene during the 3rd quarter worth about $61,000. CI Investments Inc. increased its position in BeiGene by 295.4% in the 4th quarter. CI Investments Inc. now owns 518 shares of the company's stock worth $114,000 after buying an additional 387 shares during the period. Rockefeller Capital Management L.P. grew its holdings in shares of BeiGene by 8.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 885 shares of the company's stock worth $119,000 after purchasing an additional 68 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. acquired a new stake in BeiGene in the 3rd quarter valued at $165,000. 51.43% of the stock is currently owned by hedge funds and other institutional investors.
機構投資者和對沖基金最近增加或減少了他們在公司的股份。PNC 金融服務集團有限公司在第四季度將其在百濟神州的股份權益提高了 26.4％。PNC 金融服務集團股份有限公司在上一季度額外購買 51 股股票後，擁有該公司股票的 244 股價值為 54,000 美元。中國環球資產管理有限公司Ltd. 在第三季度購買了價值約 61,000 美元的百濟神州股份的新股份。CI 投資股份有限公司在百濟神州的地位在第四季度增加了 295.4％。國際投資股份有限公司在期內額外購買 387 股股票後，現在擁有該公司股票的 518 股價值 114,000 美元。洛克菲勒資本管理有限責任公司在第三季度增長了 8.3% 在百濟神州的股份持有量。洛克菲勒資本管理有限責任公司在上一季度額外購買 68 股股份後，擁有該公司股票價值 119,000 美元的 885 股。最後，內華達州惠蒂爾信託有限公司在第三季度收購了百濟神州的新股份，價值為 165,000 美元。51.43％ 的股票目前由對沖基金和其他機構投資者擁有。
BeiGene Company Profile
百濟神州公司簡介
(Get Rating)
(取得評分)
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
百濟神州有限公司是一家全球性的科學驅動型生物技術公司，致力於開發創新且價格合理的藥物，以改善治療效果並為全球患者提供服務。該公司由王曉東和約翰·奧伊勒於 2010 年 10 月 28 日創立，總部位於肯塔基州喬治市。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on BeiGene (BGNE)
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
- Lennar Raises The Roof With Q1 Results: Don't Chase It Higher
- Universal Insurance: Navigating Florida's Insurance Crisis
- Meme-Stock AMC's Plan To Convert More Shares Headed For Court
- 免費獲取有關百濟神州（BGNE）的研究報告
- 運動達集團 A 股增長型股票在 2023 年下注嗎？
- 強有力的指導說波音公司已準備好起飛
- Lennar 提高了屋頂與 Q1 結果:不要追逐它更高
- 普遍保險：駕馭佛羅里達州的保險危機
- 模因股票 AMC 的計劃將更多股票轉換為法院
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.
接收百濟神州日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收百濟神州和相關公司的最新新聞和分析師評級的簡要每日摘要。